secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2024-11-19T23:59:59+00:00
Accession:  0001628280-24-048527
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre Therapeutics prices $200M public offering of 7.275M shares at $27.50
--------------------------------------------------------------------------

- Offering includes 7,275,000 shares of common stock at $27.50; underwriters have 30-day option for 1,091,250 additional shares.
- Gross proceeds expected to be approximately $200M before expenses; net proceeds plus existing cash expected to fund operations into H2 2028.
- Underwriters: Jefferies, Goldman Sachs, Evercore, Guggenheim; closing expected Nov 20, 2024.
- Offered pursuant to Form S-3 shelf registration; prospectus supplement filed Nov 19, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000162828024048527/0001628280-24-048527-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000162828024048527/syre-20241118.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-048527

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer